BACKGROUND:The conventional antiviral treatment of chronic hepatitis related to hepatitis C virus (HCV) often leads to anemia. In this case, it is necessary to reduce ribavirin dose or stop treatment, thus reducing the rate of sustained virological response.AIM:We investigated whether epoetin alpha administration improves treatment adherence and leads to higher percentage of response at the end of therapy and sustained virological response.METHODS:Two hundred and fourteen individuals with genotype 1b HCV-related chronic hepatitis underwent treatment with pegylated (peg)-interferon alpha-2A 180 μg once weekly and ribavirin 1,000-1,200 mg/day; 174 were responders. Forty individuals completed treatment with no hemoglobin reduction; 134 developed anemia during therapy. Anemic responders were distributed randomly into two groups: group 1 continued therapy with epoetin alpha addiction; group 2 continued antiviral therapy with ribavirin reduction only.RESULTS:Patients in group 1 achieved better control of hemoglobin levels (13.8 ± 1.2 g/dl at the end of therapy) than those in group 2 (11.5 ± 0.8 g/dl). Sustained virological response was 59.7% in group 1 compared with 34.4% in group 2 (p<0.01).CONCLUSIONS:In patients with 1b HCV-related chronic hepatitis who develop anemia during antiviral treatment, administration of epoetin alpha increases hemoglobin levels and the end-of-treatment rate and sustains virological response by improving treatment adherence.
|Titolo:||Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis|
|Data di pubblicazione:||2010|
|Citazione:||Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis / BERTINO G; ARDIRI AM; BOEMI PM; RUGGERI IM; CALVAGNO GS; IERNA D; SANTONOCITO MM; BRUNO CM; VALENTI M; BOEMI R; NAIMO S; NERI S. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - 66:10(2010), pp. 1055-1063.|
|Appare nelle tipologie:||1.1 Articolo in rivista|